Bemcentinib (R428)

Katalognr.S2841 Batch:S284108

Skriv ut

Tekniska data

Formel

C30H34N8
Molekylvikt 506.64 CAS-nr. 1037624-75-1
Löslighet (25°C)* In vitro DMSO 9 mg/mL (17.76 mM)
Water Insoluble
Ethanol Insoluble
In Vivo (Tillsätt lösningsmedel till produkten individuellt och i ordning.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml betyder svårlösligt eller olösligt.
* Vänligen notera att Selleck testar lösligheten för alla förbindelser internt, och den faktiska lösligheten kan skilja sig något från publicerade värden. Detta är normalt och beror på små variationer mellan olika partier.
* Rumstempererad frakt (Stabilitetstester visar att denna produkt kan fraktas utan några kylåtgärder.)

Beredning av stamlösningar

Biologisk aktivitet

Beskrivning Bemcentinib (R428, BGB324) är en hämmare av Axl med IC50 på 14 nM, vilket visar >100 gånger selektivitet för Axl över Abl. Denna förening är också mer än 50 till 100 gånger selektiv för Axl jämfört med Mer och Tyro3, och uppvisar 100 gånger större selektivitet jämfört med InsR, EGFR, HER2 och PDGFRβ.
Mål
Axl
(Cell-free assay)
14 nM
In vitro Bemcentinib (R428) blocks the catalytic and procancerous activities of Axl. It inhibits Axl with low nanomolar activity and blocks Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. In a recent study, this compound shows a mean IC50 dose of ∼ 2.0μM for the primary CLL B cells after 24 hours of treatment and normal B-, T-, and natural killer (NK) cells show no significant amount of cell death at this dose of R428 (2.5 μM) under similar experimental conditions.
In Vivo Pharmacologic investigations reveal favorable exposure after oral administration of Bemcentinib (R428), such that treated tumors display a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, it inhibits angiogenesis in corneal micropocket and tumor models. This compound also reduces metastatic burden and extends survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis.

Protokoll (från referens)

Djurstudie:

[1]
  • Djurmodeller

    MDA-MB-231-luc-D3H2LN Intracardiac Model

  • Doseringar

    125 mg/kg

  • Administrering

    Oral, twice daily

Referenser

  • https://pubmed.ncbi.nlm.nih.gov/20145120/
  • https://pubmed.ncbi.nlm.nih.gov/21135257/

Kundvalidering av produkt

Cetuximab-resistant cells are sensitive to therapeutic blockade of AXL activity with the AXL TKI R428. Cells were treated with vehicle (-) or indicated doses of R428 for 24 hours before harvesting whole-cell lysate and immunoblotting for the indicated proteins. α-Tubulin was used as a loading control.

Data från [ Cancer Res , 2014 , 74(18), 5152-64 ]

Axl inhibitor promotes the apoptosis induced by ALK-TKIs. (A) After treated with crizotinib (100 nM), BGB324 (300 nM) or their combination for 48 h, cell apoptosis was determined by flow cytometry. (B) The induction of apoptosis by ceritinib (100 nM), BGB324 (300 nM) or their combination was examined. (C and D) Cells were treated with crizotinib (100 nM), BGB324 (300 nM) or their combination for 48 h, then whole-cell lysates were collected and the levels of indicated protein were analyzed by Western blot in (C) NB1643 and (D) SHSY5Y cells. *P < 0.05 for the indicated comparisons; ns, not significant.

Data från [ Biochem Bioph Res Co , 2014 , 10.1016/j.bbrc.2014.10.126 ]

<p>B) The processing of AXL is increased by an AXL kinase inhibitor. Panc-28 cells were incubated overnight with DMSO or 150 nM R428, a selective AXL kinase inhibitor, before examining by Western blot the levels of endogenous AXL-FL and AXL-CTF (C-20; left). Levels of AXL-CTF in DAPT-treated cells were quantified as described above and unpaired Student’s t test was employed for the analysis (right). Data are shown as means±SEM (n = 4). ***P<0.001.</p>

, , FASEB J, 2017, 31(4):1382-1397

Flow cytometry analysis showing band 3/α4 integrin expression of luciferase and TET2-knockdown CFU-E cells cultured for 13 days in the presence of DMSO or 0.2 μM R428.

Data från [ , , Blood, 2018, doi:10.1182/blood-2018-05-853291 ]

Sellecks Bemcentinib (R428) Har citerats av 142 Publikationer

Pre-adaptation of stem cell-derived islet organoids to hypoxia via zinc transportation inhibition drives angiogenesis [ Cell Stem Cell, 2026, 33(4):676-694.e10] PubMed: 41932324
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy [ Cell Stem Cell, 2025, S1934-5909(25)00265-6] PubMed: 40812300
Tumor initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice [ J Clin Invest, 2025, e180893] PubMed: 39774471
Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment [ Front Immunol, 2025, 16:1601420] PubMed: 40539073
Synaptotagmin-7 deficit causes insulin hypoactivity and contributes to behavioral alterations in mice [ iScience, 2025, 28(5):112354] PubMed: 40330888
Geranylgeranyl diphosphate synthase deficiency impairs efferocytosis and resolution of acute lung injury [ Respir Res, 2025, 26(1):189] PubMed: 40380222
FRA1 drives melanoma metastasis through an actionable transcriptional network [ bioRxiv, 2025, 2025.06.07.658418] PubMed: 40661443
Directed differentiation of pancreatic δ cells from human pluripotent stem cells [ Nat Commun, 2024, 15(1):6344] PubMed: 39068220
CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer [ Nat Commun, 2024, 15(1):2818] PubMed: 38561369
AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia [ Theranostics, 2024, 14(7):2656-2674] PubMed: 38773967

RETURPOLICY
Selleck Chemicals villkorslösa returpolicy säkerställer en smidig online-shoppingupplevelse för våra kunder. Om du på något sätt är missnöjd med ditt köp kan du returnera artikeln/artiklarna inom 7 dagar efter mottagandet. I händelse av produktkvalitetsproblem, antingen protokollrelaterade eller produktrelaterade problem, kan du returnera artikeln/artiklarna inom 365 dagar från det ursprungliga köpdatumet. Vänligen följ instruktionerna nedan vid retur av produkter.

FRAKT OCH FÖRVARING
Sellecks produkter transporteras i rumstemperatur. Om du tar emot produkten i rumstemperatur kan du vara trygg; Sellecks kvalitetskontrollavdelning har utfört experiment för att verifiera att placering i normal temperatur under en månad inte påverkar den biologiska aktiviteten hos pulverprodukter. Efter insamling ska produkten förvaras i enlighet med de krav som beskrivs i databladet. De flesta av Sellecks produkter är stabila under de rekommenderade förhållandena.

EJ AVSEDD FÖR ANVÄNDNING PÅ MÄNNISKOR, INOM VETERINÄRDIAGNOSTIK ELLER FÖR TERAPEUTISKT BRUK.